MYGN $25.670.16 (0.6%)MYGN Profile
SECTOR
Health Care
INDUSTRY
Medical Diagnostics & Research
Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease or tailor treatment for already diagnosed patients. The firm produces myRisk, a 28-gene panel with the capability to identify the elevated risk of developing eight types of cancer. Other diagnostic products include BRACAnalysis CDx, GeneSight, Vectra DA, and Prolaris. The firm also offers biomarker discovery and companion diagnostic services to pharmaceutical and biotechnology companies.
MYGN Earnings
Earnings Per Share (EPS)
-0.28
Price To Earnings Ratio (P/E)
--
2nd Quarter Earnings Report
for Apr, May & Jun Tue, Aug 13, 2019 (115 days ago) Since Earnings Report -43.3%
3rd Quarter Earnings Report
for Jul, Aug & Sep Mon, Nov 4, 2019 (32 days ago) Since Earnings Report -24.1% MYGN Dividend
Ex-Dividend Date
--
Dividend Pay Date
--
Dividend Payments
-- MYGN Charts
All Time High $69.00 Mon, Nov 6, 2000
|
| MEDICAL DIAGNOSTICS & RESEARCH |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Symbol | Price | Day | YTD |
|---|---|---|---|
| MYGN | $25.67 | -0.6% | -11.5% |
Kraft Heinz & Western Digital.
Linde, Avery Dennison Corp, Mosaic Co, Sociedad Quimica y Minera S.A. Common Stock & Kronos Worldwide Inc.
Apollo Global Management LLC, WPP plc American Depositary Shares & Medical Properties Trust Inc.
